Myocardial injury in the patient with COVID-19. Clinical implications.
Article Sidebar
Published:
Jun 3, 2020
Keywords:
COVID-19, Troponins, Myocardial injury
Main Article Content
Abstract
Increased levels of cardiac troponins, natriuretic peptides, and D-dimer have a prognostic value in patients with SARS-CoV-2 infection (COVID-19) with increased risk of acute myocardial infarction, myocarditis, heart failure, cardiac arrest, arrhythmias, and sudden death. It is important to recognize cardiac and pulmonary concomitant involvement in the same patient, since viral infections can produce an increased risk of myocardial infarction, heart failure, and cardiac arrhythmias with different mechanisms. Presentation may be sudden or as decompensation of an underlying condition. Myocardial injury is one of these possible presentations, being a recently described entity that consist of troponin elevation, compatible clinical manifestations, without angiographic evidence of coronary lesions. We present a review about its manifestation within COVID-19.
Article Details
How to Cite
1.
Bono J, Barcudi R, Sarmiento PE. Myocardial injury in the patient with COVID-19. Clinical implications. Rev Arg de Ter Int. [Internet]. 2020 Jun. 3 [cited 2024 Nov. 22];37(2). Available from: https://revista.sati.org.ar/index.php/MI/article/view/718
Section
Reviews
The magazine does not retain the reproduction rights (copyright) so the authors can republish their works with the sole mention of the original publication source.
References
Bibliografía
1. Zhonghua Liu Xing Bing Xue Za Zhi. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. 2020;41(2):145‐151. doi:10.3760/cma.j.issn.0254-6450.2020.02.003
2. Shi S, Qin M, Shen B et al. Association of Cardiac Injury with Mortality in hospitalized patients with COVID-19 in Wuhan, China JAMA Cardiology. 2020. doi:10.1001/jamacardio.2020.0950
3. Fried J, Ramasubbu K, Bhatt R, et al. The Variety of Cardiovascular Presentations of COVID-19 10.1161/CIRCULATIONAHA.120.047164
4. Thygesen K, Alpert J, Jaffe A et al. Fourth universal definition ofmyocardial infarction (2018). European Heart Journal (2019) 40, 237–269 doi:10.1093/eurheartj/ehy462 5. Mehra M, Desai S, Kuy SR et al Cardiovascular Disease, Drug Therapy and Mortality in COvid 19. New England J Medicine; May 1 2020. DOI: 10.1056/NEJM oa2007621. 6. Guo T, Fan Y, Chen M et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID 19). JAMA Cardiology March 27, 2020. JAMA Cardiol. Doi:10.1001/jamacardio. 2020.1017. 7. Lippi G, Plebani M Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med 2020. Doi:10.1515/cclm-2020-0198. 8. Lippi G., Lavie C. Sanchis-Gomar F. Cardiac Troponin I in Patients with Coronariovirus Disease 2019 (COVID-19): Evidence from a Meta-analysis. Progress in Cardiovascular Diseases. 2020. Doi.org/10.1016/j.pcard.2020.30.001. 9. Zunyou Wu, and Jennifer M. McGoogan. ,Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention JAMA April 7, 2020 Volume 323, Number 13 10. Zhou F, Yu T, Du R et al. Clinical course and risk factor for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062 8
11. Madjid M, Safa-Naeini P, Solomon S et al. Potential Effects of Coronarviruses on the Cardiovascular System. A Review. JAMA Cardiology. Online March 27, 2020. Doi: 10.1001/jamacardio.2020.1286.
12. Spiezia L, Boscolo A, Poletto F et al. COVID-19-Related Severe Hypercoagulability in
Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thromb.Haemost 2020 abril on line)doihttps//doiorg/10.1055/s0040-1710018 1ssN0340-624
13. McCartney P, Maznyczka AM, Eteiba H, et al. Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time. J AM COLL CARD I OLOGY 2020; 75;12
14. Inciardi RM, Lupi L, Zaccone G et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID 19). JAMAM Cardiol 2020. March 27 )Epub ahead of print)
15. Bangalore S, Sharma A, Sltwiner A. et al. ST Segment Elevation in Patients with Covid 19. A case series. N England J Medicine Abril 17, 2020. DOI:10.1056/NEJMc2009020
16. Tavazzi G, Pellegrini C, Maurelli M et al. Myocardial Localization of coronavirus in COVID-19 cardiogenic shock Eur J Heart Fail 2020. April10 (Epub a head of print).
17. Giulio G. Stefanini, et al. ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes 10.1161/CIRCULATIONAHA.120.0475251.
18. Chapman A, Bularga A, Mills NA High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19.
10.1161/CIRCULATIONAHA.120.047008
19. Chen T, Wu D, Chen H et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091 http://dx.doi.org/10.1136/bmj.m1091
20. American College of Cardiology: Troponin and BNP Use in COVID-19. Available online at Abril 6, 2020 https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25 troponinand-bnp-use-in-covid19.
21. COVID-19 rapid guideline: acute myocardial injury. www.nice.org.uk/guidance/ng171
22. Hendren NS, Drazner MH, Bozkurt B et al. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. 10.1161/CIRCULATIONAHA.120.047349
1. Zhonghua Liu Xing Bing Xue Za Zhi. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. 2020;41(2):145‐151. doi:10.3760/cma.j.issn.0254-6450.2020.02.003
2. Shi S, Qin M, Shen B et al. Association of Cardiac Injury with Mortality in hospitalized patients with COVID-19 in Wuhan, China JAMA Cardiology. 2020. doi:10.1001/jamacardio.2020.0950
3. Fried J, Ramasubbu K, Bhatt R, et al. The Variety of Cardiovascular Presentations of COVID-19 10.1161/CIRCULATIONAHA.120.047164
4. Thygesen K, Alpert J, Jaffe A et al. Fourth universal definition ofmyocardial infarction (2018). European Heart Journal (2019) 40, 237–269 doi:10.1093/eurheartj/ehy462 5. Mehra M, Desai S, Kuy SR et al Cardiovascular Disease, Drug Therapy and Mortality in COvid 19. New England J Medicine; May 1 2020. DOI: 10.1056/NEJM oa2007621. 6. Guo T, Fan Y, Chen M et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID 19). JAMA Cardiology March 27, 2020. JAMA Cardiol. Doi:10.1001/jamacardio. 2020.1017. 7. Lippi G, Plebani M Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med 2020. Doi:10.1515/cclm-2020-0198. 8. Lippi G., Lavie C. Sanchis-Gomar F. Cardiac Troponin I in Patients with Coronariovirus Disease 2019 (COVID-19): Evidence from a Meta-analysis. Progress in Cardiovascular Diseases. 2020. Doi.org/10.1016/j.pcard.2020.30.001. 9. Zunyou Wu, and Jennifer M. McGoogan. ,Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention JAMA April 7, 2020 Volume 323, Number 13 10. Zhou F, Yu T, Du R et al. Clinical course and risk factor for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062 8
11. Madjid M, Safa-Naeini P, Solomon S et al. Potential Effects of Coronarviruses on the Cardiovascular System. A Review. JAMA Cardiology. Online March 27, 2020. Doi: 10.1001/jamacardio.2020.1286.
12. Spiezia L, Boscolo A, Poletto F et al. COVID-19-Related Severe Hypercoagulability in
Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thromb.Haemost 2020 abril on line)doihttps//doiorg/10.1055/s0040-1710018 1ssN0340-624
13. McCartney P, Maznyczka AM, Eteiba H, et al. Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time. J AM COLL CARD I OLOGY 2020; 75;12
14. Inciardi RM, Lupi L, Zaccone G et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID 19). JAMAM Cardiol 2020. March 27 )Epub ahead of print)
15. Bangalore S, Sharma A, Sltwiner A. et al. ST Segment Elevation in Patients with Covid 19. A case series. N England J Medicine Abril 17, 2020. DOI:10.1056/NEJMc2009020
16. Tavazzi G, Pellegrini C, Maurelli M et al. Myocardial Localization of coronavirus in COVID-19 cardiogenic shock Eur J Heart Fail 2020. April10 (Epub a head of print).
17. Giulio G. Stefanini, et al. ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes 10.1161/CIRCULATIONAHA.120.0475251.
18. Chapman A, Bularga A, Mills NA High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19.
10.1161/CIRCULATIONAHA.120.047008
19. Chen T, Wu D, Chen H et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091 http://dx.doi.org/10.1136/bmj.m1091
20. American College of Cardiology: Troponin and BNP Use in COVID-19. Available online at Abril 6, 2020 https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25 troponinand-bnp-use-in-covid19.
21. COVID-19 rapid guideline: acute myocardial injury. www.nice.org.uk/guidance/ng171
22. Hendren NS, Drazner MH, Bozkurt B et al. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. 10.1161/CIRCULATIONAHA.120.047349